Major Tech Firm Annual Revenue Exceeds 400 Billion Yuan

A Chinese company reported that overseas revenue accounted for 68.2 percent of its total income in 2025. A Chinese biotechnology company has reduced its preclinical candidate (PCC) development cycle from an average of 5.5 years to between 12 and 18 months. A Chinese biotechnology firm has successfully shortened its antibody development cycle, enabling the production of high-affinity monoclonal antibodies. A Chinese biotechnology firm is expanding its antibody pipeline to address bispecific antibody challenges. The firm reported over 150 new collaboration projects in 2025, bringing total cumulative agreements to over 350. A Chinese biotechnology firm has reported robust business growth despite pressure on 2025 growth rates. A Chinese biotechnology firm is utilizing AI to enhance antibody screening efficiency. The company reported annual revenue of 457.287 billion yuan, marking a 25% year-on-year increase. Attributable profit reached 41.643 billion yuan, representing a 76.02% increase compared to the previous year. An annual earnings report shows yearly revenue surpassed 400 billion yuan, reaching 457.287 billion yuan, a 25% year-on-year increase. Attributable profit rose 76.02% to 41.643 billion yuan, while adjusted net profit reached 39.166 billion yuan.